Interferon β-1b Treatment in a Korean Girl with Multiple Sclerosis
다발성 경화증 환아에서 Interferon β-1b의 효과적인 치료 증례
Hyo Jeong Kim ; Heung Dong Kim ; Hoon-Chul Kang ; Joon Soo Lee
Journal of the Korean Child Neurology Society (대한소아신경학회지), Vol.21(1) : 28~32, 2013
Journal of the Korean Child Neurology Society (대한소아신경학회지)
Here we report a case of pediatric multiple sclerosis treated with interferon β-1b. Interferon beta is widely used in adult patients with multiple sclerosis (MS). However, its effects and safety in pediatric patients have not been well established. Although supporting data are limited, the use of disease modifying therapies (DMTs) such as interferon β-1b is recommended early in treatment of children with MS. Reports of interferon beta treatment in pediatric MS patients in Korea are rare. In this report, we describe a Korean girl who was effectively treated with interferon β-1b for three years. There were no relapses or serious side effects. Therefore, this report provides evidence supporting the use of interferon beta in pediatric MS patients in Korea and other Asian countries. We also reviewed current medical treatment of MS, including some DMTs and second-line treatment options such as natalizumab and cyclophosphamide, and several new oral agents such as fingolimod.